Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia.
(2008) In Angiology 59. p.542-548- Abstract
- To evaluate relationships between lipid-lowering therapy, inflammation, and 3-year mortality in critical limb ischemia (CLI), 259 consecutive CLI patients underwent evaluation of medication, tumor necrosis factor-alpha, interleukin-6 (IL6), neopterin, high-sensitivity C-reactive protein (hs-CRP), 8-epi-PGF2alpha, and endothelin-1. Mortality was assessed after 3 years. Sixty-one patients (24%) were on lipid-lowering therapy and 59 patients (97%) on statins. Patients on lipid-lowering therapy were younger and showed lower low-density lipoprotein cholesterol, hs-CRP, and IL-6 levels than patients without therapy. Three-year survival was higher among patients on lipid-lowering therapy. In logistic regression, the effect of lipid-lowering... (More)
- To evaluate relationships between lipid-lowering therapy, inflammation, and 3-year mortality in critical limb ischemia (CLI), 259 consecutive CLI patients underwent evaluation of medication, tumor necrosis factor-alpha, interleukin-6 (IL6), neopterin, high-sensitivity C-reactive protein (hs-CRP), 8-epi-PGF2alpha, and endothelin-1. Mortality was assessed after 3 years. Sixty-one patients (24%) were on lipid-lowering therapy and 59 patients (97%) on statins. Patients on lipid-lowering therapy were younger and showed lower low-density lipoprotein cholesterol, hs-CRP, and IL-6 levels than patients without therapy. Three-year survival was higher among patients on lipid-lowering therapy. In logistic regression, the effect of lipid-lowering therapy on 3year survival was significant with inflammatory markers entered into the model one by one but disappeared when all inflammatory markers were entered into the model together. In conclusion, hs-CRP and IL-6 levels were lower and 3-year survival was higher in CLI patients on lipid-lowering therapy. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1147797
- author
- Isma, Nazim LU ; Barani, Jamal LU ; Mattiason, Ingrid ; Lindblad, Bengt LU and Gottsäter, Anders LU
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Angiology
- volume
- 59
- pages
- 542 - 548
- publisher
- SAGE Publications
- external identifiers
-
- wos:000260483500003
- pmid:18388063
- scopus:54049106192
- ISSN
- 0003-3197
- DOI
- 10.1177/0003319707306144
- language
- English
- LU publication?
- yes
- id
- 0612ecdb-8010-4a9d-bb23-a80a972af0fa (old id 1147797)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/18388063?dopt=Abstract
- date added to LUP
- 2016-04-04 09:43:43
- date last changed
- 2022-04-23 22:00:28
@article{0612ecdb-8010-4a9d-bb23-a80a972af0fa, abstract = {{To evaluate relationships between lipid-lowering therapy, inflammation, and 3-year mortality in critical limb ischemia (CLI), 259 consecutive CLI patients underwent evaluation of medication, tumor necrosis factor-alpha, interleukin-6 (IL6), neopterin, high-sensitivity C-reactive protein (hs-CRP), 8-epi-PGF2alpha, and endothelin-1. Mortality was assessed after 3 years. Sixty-one patients (24%) were on lipid-lowering therapy and 59 patients (97%) on statins. Patients on lipid-lowering therapy were younger and showed lower low-density lipoprotein cholesterol, hs-CRP, and IL-6 levels than patients without therapy. Three-year survival was higher among patients on lipid-lowering therapy. In logistic regression, the effect of lipid-lowering therapy on 3year survival was significant with inflammatory markers entered into the model one by one but disappeared when all inflammatory markers were entered into the model together. In conclusion, hs-CRP and IL-6 levels were lower and 3-year survival was higher in CLI patients on lipid-lowering therapy.}}, author = {{Isma, Nazim and Barani, Jamal and Mattiason, Ingrid and Lindblad, Bengt and Gottsäter, Anders}}, issn = {{0003-3197}}, language = {{eng}}, pages = {{542--548}}, publisher = {{SAGE Publications}}, series = {{Angiology}}, title = {{Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia.}}, url = {{http://dx.doi.org/10.1177/0003319707306144}}, doi = {{10.1177/0003319707306144}}, volume = {{59}}, year = {{2008}}, }